JPWO2019175220A5 - - Google Patents

Claims (32)

a) As the variable heavy chain complementarity determining regions 3, aCD25-a-672-HCDR3 amino acid sequence (SEQ ID NO: 4) ,
b) The aCD25-a-672-HCDR1 amino acid sequence (SEQ ID NO: 2) as the variable heavy chain complementarity determining regions 1
c) As the variable heavy chain complementarity determining regions 2, aCD25-a-672-HCDR2 amino acid sequence (SEQ ID NO: 3),
d) The aCD25-a-672-LCDR1 amino acid sequence (SEQ ID NO: 6) as the variable light chain complementarity determining regions 1.
e) The aCD25-a-672-LCDR2 amino acid sequence (SEQ ID NO: 7) as the variable light chain complementarity determining regions 2 and
f) aCD25-a-672-LCDR3 amino acid sequence as variable light chain complementarity determining regions 3 (SEQ ID NO: 8)
Anti-CD25 antibody or antigen-binding fragment thereof comprising. 1 . An antibody or an antigen-binding fragment thereof. Claim 1 which is a monoclonal antibody, a domain antibody, a Fab fragment, an F (ab') 2 fragment, a single chain variable fragment (scFv), a scFv-Fc fragment, a single chain antibody (scAb) or a single domain antibody. Or the antibody according to 2 or an antigen-binding fragment thereof. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 3 , which is a rabbit, mouse, chimeric, humanized or fully human antigen-binding antibody. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 4 , wherein the antibody is selected from the group consisting of IgG1, IgG2, IgG3 and IgG4 isotype antibodies. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 5 , which is contained in a bispecific antibody, a multispecific antibody, or an immune complex further comprising a therapeutic agent or a diagnostic agent. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 6 , which does not inhibit the binding of interleukin-2 (IL-2) to CD25. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 7 , which does not inhibit the signal transduction of interleukin-2 (IL-2) via CD25. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 8 , which has been defucosylated. An antibody or antigen-binding fragment thereof that specifically binds to an epitope of human CD25, wherein the epitope contains one or more amino acid residues contained in amino acids 42 to 56 and / or 150 to 160 of SEQ ID NO: 1. , Antibodies or antigen-binding fragments thereof . The antibody or antigen-binding fragment thereof according to claim 10 , wherein the epitope comprises amino acids 42 to 56 and 150 to 160 of SEQ ID NO: 1. The affinity maturation variant of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 11 . A nucleic acid molecule encoding the antibody or antigen-binding fragment thereof according to any one of claims 1 to 12 . A nucleic acid vector containing the nucleic acid molecule according to claim 13 . A host cell comprising the nucleic acid vector of claim 14 . A method for producing the antibody or antigen-binding fragment thereof according to any one of claims 1 to 12 , which comprises culturing the host cell according to claim 15 . A composition comprising the antibody according to any one of claims 1 to 12 or an antigen-binding fragment thereof. 17. The composition of claim 17 , further comprising a pharmaceutically acceptable carrier or excipient. The composition according to claim 17 or 18 , which is used in the treatment of cancer. A composition for treating cancer , comprising an antibody or an antigen - binding fragment thereof that competes with the antibody according to any one of claims 1 to 12 for binding to CD25. The composition according to claim 19 or 20 , further characterized in which the second agent is administered simultaneously or sequentially in any order. 21. The composition of claim 21 , wherein the second agent is an immune checkpoint inhibitor or cancer vaccine. 22. The composition of claim 22 , wherein the second agent is an immune checkpoint inhibitor and the immune checkpoint inhibitor is a PD-1 antagonist. 23. The composition of claim 23 , wherein the PD-1 antagonist is an anti-PD-1 antibody or an anti-PD-L1 antibody. The composition according to any one of claims 19 to 24 , wherein the cancer comprises a solid tumor. The composition according to any one of claims 19 to 24 , wherein the cancer comprises a hematological cancer tumor. A composition for depleting regulatory T cells in a tumor , wherein the antibody according to any one of claims 1 to 12 or an antigen-binding fragment thereof , or the binding of CD25 is associated with the binding of claims 1 to 12 . A composition comprising an antibody competing with the antibody according to any one of the above or an antigen-binding fragment thereof. 27. The composition of claim 27 , wherein the tumor is a solid tumor. 27. The composition of claim 27 , wherein the tumor is a hematological cancer tumor. A kit comprising the composition according to claim 17 or 18 in a container. A method for producing an anti-CD25 antibody, which comprises preparing the antibody according to any one of claims 1 to 12 and subjecting the antibody to affinity maturation. Has a greater affinity for CD25 than the parent antibody, the method. A method for preparing a pharmaceutical composition, wherein an antibody prepared according to the method according to claim 31 is prepared, and the antibody is co-blended with at least one or more pharmaceutically acceptable excipients. Methods, including what to do.